JPMorgan Chase & Co. Reiterates “Overweight” Rating for AstraZeneca (LON:AZN)

AstraZeneca (LON:AZN)‘s stock had its “overweight” rating reaffirmed by stock analysts at JPMorgan Chase & Co. in a research note issued on Friday, Marketbeat.com reports. They presently have a £140 ($175.50) target price on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 33.66% from the stock’s previous close.

A number of other research firms also recently issued reports on AZN. Shore Capital restated a “buy” rating on shares of AstraZeneca in a research report on Thursday, November 7th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a £110 ($137.90) target price on shares of AstraZeneca in a research report on Tuesday, September 3rd. Finally, Berenberg Bank restated a “buy” rating and set a £150 ($188.04) target price on shares of AstraZeneca in a research report on Monday, September 2nd. One analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, AstraZeneca has a consensus rating of “Moderate Buy” and a consensus target price of £104.12 ($130.53).

AstraZeneca Stock Up 4.1 %

Shares of LON:AZN opened at £104.74 ($131.30) on Friday. AstraZeneca has a 12 month low of GBX 9,461 ($118.60) and a 12 month high of £133.88 ($167.83). The company’s 50-day moving average price is £113.52 and its two-hundred day moving average price is £120.66. The company has a quick ratio of 0.59, a current ratio of 0.89 and a debt-to-equity ratio of 84.97. The firm has a market cap of £162.35 billion, a P/E ratio of 3,325.08, a P/E/G ratio of 0.86 and a beta of 0.17.

Insider Activity at AstraZeneca

In other AstraZeneca news, insider Michel Demare bought 2,000 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was acquired at an average cost of GBX 118 ($1.48) per share, with a total value of £2,360 ($2,958.51). Also, insider Pascal Soriot bought 20,000 shares of the stock in a transaction that occurred on Thursday, November 14th. The shares were acquired at an average cost of £102.03 ($127.91) per share, with a total value of £2,040,600 ($2,558,104.55). Insiders have bought 23,500 shares of company stock worth $223,316,000 in the last ninety days. Company insiders own 0.04% of the company’s stock.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.